Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | PRKACA | P17612 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.65 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8050491 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL29069514 | 0.90 | CYP1A2 (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL29069510 | 0.90 | CYP1A2 (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL11090821 | 0.87 | CYP1A2 (0.77) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL14950253 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL631998 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL13790336 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL699458 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL4881152 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 | |
| SCHEMBL699457 | 0.86 | RELA (0.81) | CYP1A2KDM4ECYP2D6HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119792190-A | Multifunctional nano-enzyme composite hydrogel and preparation method and application thereof | 安徽中医药大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119792190-A | Multifunctional nano-enzyme composite hydrogel and preparation method and application thereof | 安徽中医药大学 | 2025-04-11 | — | — | CN | disclosed |
| EP-3674381-B1 | ORGANIC OPTICAL MATERIAL | JAPAN SCIENCE & TECH AGENCY (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20200284946-A1 | ORGANIC OPTICAL MATERIAL | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-3674381-A1 | ORGANIC OPTICAL MATERIAL | Japan Science and Technology Agency (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-9868705-B2 | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| WO-2015048246-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-02 | — | — | WO | disclosed |
| US-6020436-A | GRAFT POLYMERIZATION | THE CHROMALINE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-5506089-A | CONTAINING HETEROCYCLIC QUATERNARY PENDANT GROUP | THE CHROMALINE CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5360864-A | Process for preparation of photosensitive composition | ULANO CORPORATION (US) | 1994-11-01 | — | — | US | disclosed |
| US-5358999-A | Polyvinyl acetals | ULANO CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
| US-5330877-A | Photoresists based on quaternary ammonium derivatives of an acetal resin | ULANO CORPORATION (US) | 1994-07-19 | — | — | US | disclosed |
| US-5326669-A | Pyridinium-containing polyvinyl acetals | ULANO CORPORATION (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0290591-B1 | MATERIALS WITH NITROGENOUS SIX-MEMBERED RINGS | MERCK PATENT GmbH (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4925770-A | COATING, PRIOR TO LIGHT EXPOSURE OF PHOTORESIST LAYER, A PHOTO-BLEACHABLE COMPOUND AND A WATER SOLUBLE POLYMER | DIRECTOR GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0246885-A2 | A contrast-enhancing agent for photolithography | Japan as represented by Director-General, Agency of Industrial Science and Technology (JP) | 1987-11-25 | — | — | EP | disclosed |
| US-3965102-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | AR, FSHR, ESRRB | CYP1A2 2265/4885KDM4E 1583/4885CYP2D6 3180/4885 |
| US-20200284946-A1 | ORGANIC OPTICAL MATERIAL | SLC43A1, SLCO4C1, SLCO1A2 | CYP1A2 2498/4885KDM4E 3282/4885CYP2D6 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.